基化疗中的心脏毒性:机制,表现和管理
Betty Rachma1,2, Merlyna Savitri1,2,3, Henry Sutanto1,2
1Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, 60132, Indonesia.
Cancer pathogenesis and therapy
|April 4, 2025
概括
化疗可能会伤害心脏. 本综述详细介绍了基于的化疗心脏毒性机制,检测和管理,为更好的患者护理提供了见解.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基于的化疗对于治疗癌症至关重要,但可能导致心脏损伤 (心脏毒性).
- 了解和管理这种心脏毒性对于改善癌症患者的治疗结果至关重要.
- 本综述综合了当前关于诱导心脏毒性的知识.
研究的目的:
- 综合审查与基化疗相关的心脏毒性机制,临床特征,诊断方法和管理策略.
- 突出最近的进展和未来的研究方向,以减轻产生的心脏不良影响.
主要方法:
- 关于基化疗心脏毒性的机制,临床表现,检测和管理的文献综述.
- 诊断工具的分析,包括心声回声,心脏MRI和生物标志物.
- 探索当前和新兴的治疗干预和个性化医疗方法.
主要成果:
- 机制包括氧化应激,DNA损伤和改变的信号通路.
- 临床影响范围从轻微的症状到严重的疾病,如Takotsubo心肌病.
- 通过心脏监测和诊断工具进行早期检测至关重要.
- 管理包括心脏保护剂,替代方案和新型配方 (例如,纳米脂肪体,立体体).
结论:
- 基于的化疗具有显著的心脏毒性风险,需要仔细监测和管理.
- 结合早期检测,心脏保护策略和个性化医疗的综合方法是缓解这些风险的关键.
- 需要进行进一步的研究,以完善白金诱导心脏毒性的预测模型和治疗干预.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


